Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 1, January-February, p. 153–159

doi: 10.17219/acem/28626

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Immunoglobulins and Their Use in Children

Paweł Łaguna1,D, Sydonia Gołębiowska-Staroszczyk1,D, Maciej Trzaska2,D, Małgorzata Grabarczyk1,D, Michał Matysiak1,D

1 Department of Pediatrics Hematology and Oncology, Medical University of Warsaw, Poland

2 Octapharma, Poland

Abstract

Immunoglobulin preparations are one of the products of the human plasma fractionation, where the plasma is obtained, in accordance with WHO guidelines from at least 1,000 donors. These preparations contain all IgG subclasses with various antigen characteristics. In clinical practice these drugs are used as replacement therapy in patients with primary and secondary immunodeficiencies as well as immunomodulatory therapy in many autoimmune diseases and systemic inflammatory diseases. Here we present characteristics of i.v. polyvalent, human immunoglobulin preparations available on the Polish market and the possibilities of their use in clinical practice, in children with hematological diseases. Considering the very low consumption of immunoglobulin preparations in our country as compared to other European countries, we would like to draw the attention of medical professionals, especially pediatricians and haematologists, to the benefits that stem from the use of these drugs in the therapy of children with haematological diseases. Our work will also facilitate the choice of an optimal polyvalent human immunoglobulin preparation for a particular patient.

Key words

i.v. immunoglobulin preparations, immune thrombocytopenic purpura, children.

References (23)

  1. Cherin P, Cabane J: Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use. Biodrugs 2010, 24, 211–223.
  2. Wick M, Wick M, Heberger S, Simon H, Fateh-Moghadam A: Quality control of IgG preparations by protein analysis. Infusionsther Transfusionsmed 1996, 23 (suppl. 4), 55–59.
  3. Siegel J: Intravenous immune globulins: therapeutic, pharmaceutical, & cost considerations. Pharm Practice News 1994, 21, 12–14.
  4. Cohn EJ, Strong LE, Hughes Jr WL, Mulford DJ, Ashworth JN, Melin M, Taylor HL: Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. Journal of the American Chemical Society 68, 459–475, 1946.
  5. WHO Technical Report Series, No, 840, 1994. Annex 2. Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives (Requirements for Biological Substances, No, 27, revised 1992)
  6. Gelfland EW: Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005, 28, 366–374.
  7. Hartung HP: Advances in the undentanding of the mechanism of action ofIVIg. J Neurol 2008, 255 Suppl, 3, 3–6.
  8. Looney RJ, Huggins J: Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006, 19, 3–25.
  9. Łaguna P, Trzaska M: Charakterystyka i podział rekombinowanych preparatów krzepnięcia zarejestrowanych w Polsce w leczeniu hemofilii A i B z uwzględnieniem nowej klasy czynnika uzyskiwanego z komórek ludzkich. Nowa Pediatria 4/2010, 125–128.
  10. Hooper JA: Intravenous immunoglobulins evolution of commerciaI IVIG preparations. Immunol Allergy Clin North Am 2008, 28, 765–767.
  11. Ballow M: Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007, 38 (1–3), 122–132.
  12. Lachert E, Antoniewicz-Papis J: Metody inaktywacji czynników chorobotwórczych w składnikach krwi. Journal of Transfusion Medicine 2010, tom 3, 3, 112–119.
  13. Svae TE, Frenzel W, Heger A, Römisch J: Dosing of solvent/detergent plasma versus single-donor fresh-frozen plasma. J Trauma 2007, Apr, 62, 1068–1069.
  14. Membrany. Teoria i praktyka. Redakcja: Romuald Wódzki. Fundacja rozwoju wydziału chemii. Uniwersytet Mikołaja Kopernika. Toruń 2003
  15. Yunoki M, Tanaka H, Urayama T, Hattori S: Prion removal by nanofiltration under different experimental conditions. Biologicals 2008, 36, 27–36.
  16. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000069.jsp
  17. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000071. jsp&mid=WC0b01ac05800265d0
  18. Guideline on requirements for PMF certification CPMP/BWP/4663/03. http://ec.europa.eu/health/files/eudralex/ vol-2/c/466303en_08_2004_en.pdf
  19. Lin RY, Rodriguez-Baez G, Bhargave GA, Lin H: Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004–2009. Clinical Nephrology, Vol. 76, No. 5/2011 (365–372).
  20. Wojtecka A, Kade G, Bilbin-Bukowska A, Niemczyk S: Ostre uszkodzenie nerek wymagające terapii nerkozastępczej u chorego leczonego immunoglobulinami. Pol Merk Lek 2012, XXXII, 189, 173.
  21. Siwińska-Gołębiowska H, Borysewicz G, Buława E, Hofman H, Lambert I, Kunicka A, Jankowska B, Smogorzewska E: Immunochemical properties and therapeutic usefulness of the preparation Igalina produced by Biomed Probl Med Wieku Rozwoj 1979, 8, 152–164.
  22. Gelfand EW: Selecting Appropriate IGIV Therapy. CME/CE Released: 12/16/2003. http://www.medscape.org/ viewarticle/461288
  23. Eijkhout HW, van den Broek PJ, van der Meer JW: Substitution therapy in immunodeficient patient with antiIgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003, 61, 213–217.
© Wroclaw Medical University